Title:
TRIMERIC ANTIBODIES AGAINST SARS-CoV-2 SPIKE PROTEIN
Document Type and Number:
WIPO Patent Application WO/2023/077429
Kind Code:
A1
Abstract:
The present disclosure provides trimetric antibodies and fragments having binding specificity to the SARS-CoV-2 spike protein's receptor binding domain (RBD). The trimeric antibodies and fragments have strong affinity and potent neutralization ability against the SARS-CoV-2 virus and various mutant forms. In particular, these trimeric antibodies have enhanced neutralization capabilities than their counterpart dimers and can more broadly neutralize new viral variants. The trimeric antibodies and fragments thus may be used for preventing or treating SARS-CoV-2 viral infection.
More Like This:
Inventors:
MA PEIXIANG (CN)
YANG GUANG (CN)
LERNER RICHARD A (CN)
QIANG MIN (CN)
YANG GUANG (CN)
LERNER RICHARD A (CN)
QIANG MIN (CN)
Application Number:
PCT/CN2021/129009
Publication Date:
May 11, 2023
Filing Date:
November 05, 2021
Export Citation:
Assignee:
UNIV SHANGHAI TECH (CN)
International Classes:
C07K16/00; A61K39/395; A61P31/14; C07K16/10; C12N15/62
Domestic Patent References:
| WO2017098005A1 | 2017-06-15 | |||
| WO2012049328A1 | 2012-04-19 | |||
| WO2021119497A1 | 2021-06-17 | |||
| WO2021212049A2 | 2021-10-21 | |||
| WO2001019958A2 | 2001-03-22 | |||
| WO2012045001A2 | 2012-04-05 |
Foreign References:
| CN113388030A | 2021-09-14 |
Other References:
MARTA COMPTE, SEANDEAN LYKKE HARWOOD, INES G. MUñOZ, ROCIO NAVARRO, MANUELA ZONCA, GEMA PEREZ-CHACON, AINHOA ERCE-LLAMAZARES,: "A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity", NATURE COMMUNICATIONS, vol. 9, no. 1, 1 December 2018 (2018-12-01), XP055611095, DOI: 10.1038/s41467-018-07195-w
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: